[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab

Phase 1/2Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent Melanoma (Skin)

Conditions

Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III

Trial Timeline

Jun 1, 2023 → Dec 31, 2029

NCT ID

NCT05655312

About [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab

[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab is a phase 1/2 stage product being developed by Perspective Therapeutics for Recurrent Melanoma (Skin). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05655312. Target conditions include Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05655312	Phase 1/2	Recruiting	Jun 1, 2023	Dec 31, 2029	Recurrent Melanoma (Skin)

Competing Products

20 competing products in Recurrent Melanoma (Skin)

See all competitors

Product	Company	Stage	Hype Score
KPL-914	Kiniksa Pharmaceuticals	Phase 2	47
KPL-387	Kiniksa Pharmaceuticals	Phase 2	47
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	72
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	33
Zopapogene imadenovec (Zopa)	Precigen	Approved	80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	36
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	52
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	41
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	33
PLX3397	Daiichi Sankyo	Phase 2	52
erlotinib + etoposide	Astellas Pharma	Phase 2	52
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	52
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
Eribulin Mesylate	Eisai	Pre-clinical	23
Lenvatinib + Everolimus	Eisai	Phase 1/2	41
E7090	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52
Eribulin mesilate + Irinotecan hydrochloride	Eisai	Phase 1/2	41

Other Products from Perspective Therapeutics

[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPhase 1/2

[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Phase 1/2

[203Pb]VMT-α-NETPhase 1

[212Pb] VMT-α-NETPhase 1

[203Pb]VMT01 + [68Ga]VMT02Phase 1